Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions. by Jiefeng Zhao (9090305)

Subjects:

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Characteristics of census tracts that are projected to have high (groups: 250-399 and 400+) and low (groups: 50-99 and 100-249) MHC utilization for COVID-19 vaccination before Marc... by Fatih Gezer (21485468)

Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3. by Anneli Peolsson (7867601)

Subjects:

The CONSORT flow diagram. by Anneli Peolsson (7867601)

Subjects:

Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the two groups WAD grades 2 and 3. by Anneli Peolsson (7867601)

Subjects:

Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness. by Anneli Peolsson (7867601)

Subjects:

Frequency distribution of SOLEC at baseline and follow-ups in the NSEIT and NSE groups. by Anneli Peolsson (7867601)

Subjects: